Key facts
| Firm | Lupin Limited |
|---|---|
| FEI / inspection ID | 3004819820 |
| Inspection end date | November 21, 2025 |
| Citation count | 6 |
What a Form 483 means
A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.
Citations explained
Observation 1 — l'he responsibilities an d procedures appl icable to the qu ality control
l'he responsibilities an d procedures appl icable to the qu ality control unit are not fully followed. Specifically, your quality unit did not take appropriate marke action for b:4 tcl1 P<: nf..th ..J J~..rrvg product thatJa iled to meet the re gu lat ory Acceptable Intake (A I) limit for Impurities H4) Fo r ex ample: -------~----- -------~----~(b)(4) ommercial batches o Cap sules USP P,)(4) ng, (b)(4) (b)(4) " (b)(4l ""'r, (b>(4 _; 1g (bH4l ta1 led" to meet the Al limit of 11 •1 l\TMl (b)(4) nl}J11 for(b)(4) m puri ty wh en an aly zed as a part o (bH4> ___ isk assessment Age of sample Date ofTestin11 rl11r:ino t ..._.,,.,. St rength 11/ 21 /2 0 25 Tan11l Ara s u , I nves ti g at cr SEE Pr ati~ S . Upa d hy a y , I nves-_gac~r REVERSE OF THIS PAGE l"\Sl 'EC- I 10"\AL OI.ISERV,\ n oM, rAGE I OF IS r.lGES.
Observation 2 — Equipment and utensils are not cleaned and maintained at appropriate intervals to
Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. ' Specifically, Your firm ;as..df!)l.iated_from...eo,1.io men Lcl e::i~) ilJf , wlidat i oll.J)ro i::.ed,,r..e..to .P__n_<:1,cfr validated /l rocedure is established in reducin......_ lmpuritieS@i4l :on direct and indirect product contact surfaces of shared (non-dedicated) equipment to predetermined Acceptable lntake (Al) limits. For example, A. According to your pro cedures SOP_MUM_CQA_ 0l 1679. Titled: "Cleaning Validation for Drug Products", Version: 5.0 , Effec tive 1 aLe.;..25..:Sen~ 025 , Section 5.3.1.3.7 "The worst-caseb)(4> I. hall be selectedfor cleaning va/idulion in resped lO[(b)(4) ..,_..Jmpurilie!>, including~ )(4) by r:ons idering risk focl.L> .. r*** '' 1':'u.-th,-, b: ~ procedure has detailed series o i1 actors to be evaluated in&uc:! ing ACO calculat ion fo ~(bH4> impurities in subsequent sections of tl1e_m.oce.dureJ:low.fil'~ r, your firm has deviated from tli1 s proceaure by not performing cleaning validation for P,H4).
Observation 3 — There is a failure to thoruughly review any unexplained discrepancy and the
There is a failure to thoruughly review any unexplained discrepancy and the fa ilure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. Specifically, A. O?i/Recall: The out-of-specification (OOS) investigation for Cb><4> ____..,...,...._jTab lets USP ~ g that ex hibited failing dissolution results was inade1 uate , as iITa,led to extend into manufac turing operations to identify_t e root cause. Specifically. batch !!>H4l 7 was incorporated into repackaged product batch (b)(4) by your contract parmer. Du ring stabi li ty e.stirnr. thi l repackaged batch demonstrated 00S dissolution results at the in itial time point (T=0) Of\(bH4) Subsequently, your repackagjng_partner who distributed t he product in the L;nited States, initiated a voluntary recall (Rec all Number: (b)(4) _____ pespite the recall action, no Field Alert Report (FAR) was submitted to the FDA as requir edand no manufacturing investigation was conducted to find the root cause. Your.
Observation 4 — Laboratory controls do not include the establishment of scientifically sound and appropriate
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed 10 assure th at drug products conform to appropriate standards of identity. strength, quality and purity. Speci fica!ly , Analytical test procedures for swab samp le analyses are not reliable to determine the level of actiw and degradant residual ma te ri als on the product contact areas of manufacturing equipment. Fo r example, There is no evaluation of .,H4> ~wab_sti_ck" nerionne<lJ o delt>J.;i,ninc tl 1e impact of extre1;1e conditions~ ,. ,_., ____.,., 1 ~·~:.ab stick that could potentially cause generation ot large number o f'ui-ik nown pea l<s'."x' our tirm analyzed ~H4> .:=}wab stick as blank during each swab analyses and labeled unknown peaks as "blank peak'' without de term 111mg the unpact of unknown peaks which were coe lu ting at ab0ut the same retention time as to that of active and degradant peaks to ensure reliability on swab sample test results. Du.
Observation 5 — Procedures de scribing the handling of written and oral complaints related to
Procedures de scribing the handling of written and oral complaints related to drug products are deficiently written or followed. Specifically, Your Quality Unit failed to thoroughly investigate adverse drug events (A DE) a nd market complaints relating to Lack of Effect (LOE). organoleptic defects and medical inquiry related to formulation. For example, A. On 12-Nov-2025, we observed for majority of your product quality complaints for the period of O1-Jan-2022 to 12 -Nov-2025 the batch number remained unknown. Fo r example. Table 5 Nature o f defect No. of No. o f complaints No. of complai nts witho ut complaints without bah·h batch numbers reported number s (%) IOrgan ole pti c defect (O dor 61 48 78 .7 , raste) IProduct Response I(ADE I LOE / Batch 300 243 8 1. 0 Qu a lity) Query related to 33 29 87.9 fom1U lation (b)(4) I 16 9 56.3 Your Quality Un it failed to identify trend of majority of com.
Observation 6 — The responsibilities and procedures applicable to the quality control unit are not
The responsibilities and procedures applicable to the quality control unit are not fully followed. Specifically, We observed the presence of lo gbooks titled 'Mi scellaneous Samples Jnward Reg ister' in the QC laboratory an d have li s ted num erous test sa mpl es as received with reference to 'Non-routine Protocols'. These non-routine protocols are not fou nd within your Quality Management System. Th ere is no written procedure that desc rib es what is Non routine Protocol and what is Miscellaneous sample. These logbooks with commercial product batch numbers have multiple ent ri es that do not have information on what type of tests were pe r formed , purpose of these tests and where SEE Ta mi l Aras u, Inves t i ga tor 11 / 21120 25 JREVERSE OF P ra ti k s . Upa d hy a y , lm·e s t ig at or THIS PAGE '---------'--·----------· ~ORM HI,\ ~8 .\ (09/0SI.
Lupin Limited’s FDA history
Argus HQ has recorded 2 total FDA actions tied to Lupin Limited: 0 warning letters, 0 recalls, 0 approval records, and 2 Form 483 inspection citations.
Frequently asked questions
- Where can I read the full Form 483?
- The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
- What is an FDA Form 483?
- A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
- Does this Form 483 mean Lupin Limited violated the law?
- No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
- What happens after a Form 483 is issued?
- The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.
See if this 483 escalates to a warning letter — before your auditor asks.
Free weekly briefing tracks every FDA inspection outcome.
Related enforcement actions
Full FDA history for Lupin LimitedCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2025). FDA Form 483 — Lupin Limited (November 21, 2025) — 6 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-lupin-limited-2025-11-21-3004819820
"FDA Form 483 — Lupin Limited (November 21, 2025) — 6 Citations." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-lupin-limited-2025-11-21-3004819820.
Argus HQ Research. "FDA Form 483 — Lupin Limited (November 21, 2025) — 6 Citations." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/483/fda-483-lupin-limited-2025-11-21-3004819820.
@misc{argushq_argushq_ai_483_fda_483_lupin_limited_2025_11_21_3004819820_2025,
title = {FDA Form 483 — Lupin Limited (November 21, 2025) — 6 Citations},
author = {{Argus HQ Research}},
year = {2025},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/483/fda-483-lupin-limited-2025-11-21-3004819820},
note = {Accessed: July 15, 2026}
}